Histogenics (NASDAQ:HSGX) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday.
Several other equities research analysts also recently weighed in on HSGX. Zacks Investment Research raised Histogenics from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price target on shares of Histogenics in a report on Thursday, December 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.50 price target on shares of Histogenics in a report on Tuesday, November 21st.
Histogenics (NASDAQ:HSGX) traded up $0.24 during mid-day trading on Wednesday, hitting $3.04. The stock had a trading volume of 346,257 shares, compared to its average volume of 147,781. The firm has a market capitalization of $69.90, a P/E ratio of -2.20 and a beta of 1.83. Histogenics has a 1-year low of $1.55 and a 1-year high of $3.13.
ILLEGAL ACTIVITY WARNING: “Histogenics (HSGX) Upgraded at ValuEngine” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2018/03/14/histogenics-hsgx-upgraded-at-valuengine.html.
Histogenics Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.